Skip to content
Back to Blog
Bio
2025-12-108 min read50

Investment Attraction Strategies for Bio Startups

How bio startups can develop effective strategies to attract venture capital and strategic investments for growth.

KITIM Consulting Team

Investment Attraction Strategies for Bio Startups

Securing investment is one of the most critical challenges facing bio startups. The bio sector is characterized by long development timelines, high capital requirements, and significant regulatory risk, making investor education and relationship management especially important. This guide provides practical strategies for bio startups seeking to attract investment.

Bio Investment Landscape

  • Korea bio VC investment trends: Venture capital investment in Korea's bio sector has grown steadily, reaching approximately KRW 2.5 trillion in recent years, with particular focus on cell and gene therapy, AI-driven drug discovery, and medical devices
  • Average deal size: Series A rounds for bio startups typically range from KRW 3 billion to KRW 10 billion, while Series B and beyond can reach KRW 20-50 billion
  • Investment cycle: Bio investments often follow a longer cycle than tech startups, with investors expecting a 7-10 year horizon to exit
  • Global context: Korean bio startups increasingly attract international investors, particularly for companies with global regulatory strategies
  • Investor Types

    Understanding different investor types helps tailor your pitch and partnership approach:

  • Venture capital (VC): Dedicated bio/healthcare VCs bring deep domain expertise, industry networks, and patient capital suited to long development timelines
  • Corporate VC (CVC): Pharmaceutical and healthcare company venture arms invest strategically, often seeking pipeline candidates or technology platforms that complement their business
  • Government funds: Korea Investment Corporation, KVIC, and ministry-affiliated funds provide growth capital with favorable terms, often co-investing alongside private VCs
  • Angel investors: High-net-worth individuals with bio/pharma backgrounds can provide early-stage capital and valuable mentorship, though typically in smaller amounts
  • Pitch Preparation

    A compelling bio startup pitch must balance scientific rigor with business storytelling:

  • Scientific narrative: Clearly explain the unmet medical need, your scientific approach, and why it is differentiated. Avoid excessive jargon while demonstrating deep understanding
  • Clinical and regulatory milestones: Present a clear, realistic timeline of development milestones, including IND filing, clinical trial phases, and anticipated regulatory approvals
  • Team credibility: Highlight the founding team's relevant credentials, industry experience, and advisory board members with recognized expertise
  • Market opportunity: Quantify the addressable market with credible data sources, and explain your go-to-market strategy or partnering plan
  • Financial projections: Provide realistic financial models showing capital needs, key value inflection points, and potential return scenarios
  • Due Diligence Readiness

    Being well-prepared for investor due diligence significantly accelerates the investment process:

  • IP audit: Ensure your patent portfolio is well-organized, with clear ownership, freedom-to-operate opinions, and a filing strategy covering key markets
  • Regulatory strategy: Document your regulatory pathway for each target market, including pre-IND meeting plans and anticipated regulatory requirements
  • Financial projections: Prepare detailed financial models with clearly stated assumptions, sensitivity analyses, and multiple scenario projections
  • Legal housekeeping: Ensure corporate governance, employment agreements, and licensing contracts are properly documented and up to date
  • Data room preparation: Organize all key documents in a virtual data room for efficient due diligence review
  • Negotiation Tips

  • Valuation methods: Pre-revenue bio companies are typically valued using risk-adjusted Net Present Value (rNPV) or comparable transaction analysis rather than revenue multiples
  • Term sheet key clauses: Pay particular attention to liquidation preferences, anti-dilution provisions, board composition, and protective provisions
  • Milestone-based tranching: Consider structuring investment in tranches tied to development milestones, which can align interests and potentially improve overall terms
  • Investor value-add: Evaluate investors not just on valuation but on the strategic value they bring, including industry connections, regulatory expertise, and follow-on funding capability
  • Legal counsel: Engage experienced biotech transaction attorneys to review terms and protect founder interests while maintaining investor confidence
  • How KITIM Can Help

    KITIM assists bio startups with investment readiness assessment, pitch deck development, investor introductions, and government funding applications. Our team has supported numerous bio companies in securing both private and public funding. Contact us to discuss your fundraising strategy.

    Bio StartupInvestment AttractionVenture Capital

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.